# Terumo partners with Orchestra BioMed for sirolimus-eluting balloon

Terumo Corporation has secured exclusive global development and commercialization rights to Virtue sirolimus-eluting balloon (SEB) from Orchestra BioMed, with an upfront payment of $30 million and an equity commitment of $5 million.

- Type: Partnership
- Announced: 2019-07-17
- Value: $35.0M
- Status: announced
- Products: sirolimus-eluting balloon, Virtue SEB
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Terumo](https://endata.com/companies/2811.md)
- [Terumo](https://endata.com/companies/2811.md) (partner)
- [Orchestra BioMed](https://endata.com/companies/39987.md) (partner)

## Sources

- [medicalbuyer.co.in](https://medicalbuyer.co.in/terumo-enhances-coronary-interventional-product-portfolio/), 2019-07-17: "Virtue SEB is the first and only non-coated drug-eluting angioplasty balloon that delivers a proprietary bioabsorbable, sustained-release formulation of sirolimus."
- [mpo-mag.com](https://www.mpo-mag.com/breaking-news/orchestra-biomed-partners-with-terumo-corporation-on-development-of-virtue-sirolimus-eluting-balloon/), 2019-08-01: "Orchestra BioMed Inc. has formed a global strategic partnership with Terumo Corporation for development and commercialization of Virtue Sirolimus-Eluting Balloon (SEB) in the percutaneous coronary and peripheral interventions field."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.